S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
NASDAQ:MRKR

Marker Therapeutics - MRKR Stock Forecast, Price & News

$0.30
0.00 (0.00%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.32
50-Day Range
$0.29
$0.46
52-Week Range
$0.25
$1.26
Volume
117,663 shs
Average Volume
233,071 shs
Market Capitalization
$25.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25

Marker Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
316.5% Upside
$1.25 Price Target
Short Interest
Healthy
1.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.62mentions of Marker Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

215th out of 1,038 stocks

Pharmaceutical Preparations Industry

88th out of 510 stocks

MRKR stock logo

About Marker Therapeutics (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Company Calendar

Last Earnings
11/10/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.25
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+316.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,880,000.00
Net Margins
-515.88%
Pretax Margin
-515.89%

Debt

Sales & Book Value

Annual Sales
$1.24 million
Book Value
$0.27 per share

Miscellaneous

Free Float
60,860,000
Market Cap
$25.09 million
Optionable
Optionable
Beta
1.12

Key Executives

  • Mr. Peter L. Hoang MBA (Age 50)
    Pres, CEO & Director
    Comp: $617.13k
  • Dr. Mythili Koneru M.D. (Age 44)
    Ph.D., Chief Medical Officer
    Comp: $550.14k
  • Dr. Juan F. Vera M.D. (Age 42)
    Co-Founder, COO, Chief Scientific Officer & Director
  • Mr. Michael J. Loiacono (Age 56)
    Chief Accounting Officer, Treasurer & Sec.
  • Ms. Elizabeth Donnelly
    Director of Admin.
  • Mr. Edmund Cheung
    VP of HR
  • Dr. Nadia Agopyan Ph.D.
    Sr. VP of Regulatory Affairs
  • Dr. Robert Z. Florkiewicz Sr.
    Sr. Director of Molecular Biology & Virology













MRKR Stock - Frequently Asked Questions

Should I buy or sell Marker Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRKR, but not buy additional shares or sell existing shares.
View MRKR analyst ratings
or view top-rated stocks.

What is Marker Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 1-year target prices for Marker Therapeutics' shares. Their MRKR share price forecasts range from $1.00 to $1.50. On average, they expect the company's share price to reach $1.25 in the next twelve months. This suggests a possible upside of 316.5% from the stock's current price.
View analysts price targets for MRKR
or view top-rated stocks among Wall Street analysts.

How have MRKR shares performed in 2022?

Marker Therapeutics' stock was trading at $0.95 at the start of the year. Since then, MRKR stock has decreased by 68.4% and is now trading at $0.3001.
View the best growth stocks for 2022 here
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative net margin of 515.88% and a negative trailing twelve-month return on equity of 110.00%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.11%), Long Focus Capital Management LLC (1.75%), Matrix Asset Advisors Inc. NY (0.48%), Renaissance Technologies LLC (0.18%) and Raymond James & Associates (0.11%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends
.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $0.30.

How much money does Marker Therapeutics make?

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $25.09 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.

This page (NASDAQ:MRKR) was last updated on 11/30/2022 by MarketBeat.com Staff